Core Insights - Tilray Brands (NASDAQ: TLRY) stock surged over 60% following President Donald Trump's video advocating for marijuana legalization for senior citizens, with potential Medicare coverage [1] - The stock experienced some pullback as momentum traders took profits, but rebounded with a 5.6% increase on Thursday [1] Group 1: Company Developments - Tilray is expanding its production of premium "Tilray Craft" cannabis in Germany, introducing five new cannabis flower products aimed at the medical marijuana market [3] - Currently, Tilray's European market is more significant than its U.S. market, with EMEA revenues exceeding $323 million annually compared to less than $274 million in the U.S. [5] Group 2: Financial Performance - Over the past year, Tilray has lost $2.2 billion, and its current market capitalization stands at approximately $2.2 billion [6] - Despite positive developments in production and potential market expansion, Tilray continues to face substantial financial losses [7]

Core Insights - Tilray Medical is expanding its Tilray Craft portfolio in Germany with five new cannabis flower products produced at its EU-GMP certified facility in Neumünster, reflecting its commitment to providing diverse, quality medical cannabis options for patients [1][2][3] Company Overview - Tilray Medical is dedicated to transforming lives by providing safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Craft, and has established itself as a leading supplier of medical cannabis [5] - The company has evolved from being one of the first licensed producers of medical cannabis in Canada to building GMP-certified production facilities in Portugal and Germany [5] Product Details - The new Tilray Craft products are available by prescription at pharmacies throughout Germany, showcasing the company's dedication to advancing medical cannabis innovation and supporting healthcare professionals [3] - Tilray Craft focuses on high potency flower, cultivated indoors in Neumünster, with an emphasis on precision and quality control to ensure reliable medical cannabis for patients [4] Commitment to Quality - The production process at Tilray's facility adheres to rigorous quality control standards, ensuring that the medical cannabis provided is consistent and dependable for patient needs [2][4] - The company prioritizes patient care and aims to deliver consistent, quality solutions to physicians and pharmacies, placing patients' needs first [2]